The Newburyport, Massachusetts-based active pharmaceutical ingredient (API) supplier announced the new service this week, predicting an advanced polymer-based materials development and manufacturing capability will expand its customer base.
PCI said the unit – which is based at its laboratory in Devens - is already developing a number of coating polymers, including some for drugs combining more than one ingredient, in addition to a number of coatings for medical devices and biodegradable implants.
CEO Ed Price predicted that the new unit would give PCI and advantage over its competitors, both near and far.
“PCI Synthesis is the only CMO in Massachusetts doing this kind of advanced cGMP polymer manufacturing, which is a big advantage for local life sciences and pharma firms, since we’re able to collaborate with them and their projects onsite. Advanced polymer manufacturing projects require sophisticated analytical techniques, and it is difficult to find that level of expertise.”
He added that: “In addition, PCI is the only CMO in North America that can simultaneously develop and manufacture in one organization both the API and any polymer based technology that may be required for combination products which are becoming more and more prevalent for pharmaceutical development.”
PCI’s customer base has grown substantially in the past 12 months. In June last year the firm told us it had signed up a dozen new Boston-based biotech and medical technology customers.